Aims: Although varenicline is commonly prescribed in primary care, information on smoking-related comorbidities and the effectiveness of varenicline in this context in Germany is scarce. This study assessed the efficacy and safety of varenicline in a large sample of patients seeking smoking cessation treatment through their general practitioners. The frequency of comorbidities was also evaluated. Methods: This was a 12-week, prospective, observational, non-comparative phase IV trial conducted in Germany. Abstinence rates at week 12 were evaluated by verbal reporting using the nicotine use inventory. Results: Overall, 1,391 subjects were enrolled; 1,177 received study medication and were evaluated for effectiveness and safety. At the end of the study, 71.1% (95% confidence interval 68.5–73.7) of subjects were abstinent. There were a total of 205 all-causality adverse events; 2.2% were classified as serious or severe. There were no fatal adverse events. At inclusion, 66.7% of participants had at least 1 concurrent comorbidity, with chronic obstructive pulmonary disease (35.5%), hypertension (29.6%) and depression (10.4%) being the most commonly reported. Conclusion: These real-world data indicate that varenicline is an effective and well-tolerated smoking cessation treatment when used in the primary care setting including patients with smoking-related comorbidities.

Keywords:
Smoking cessation, Varenicline, Observational study, Primary care
1.
Hannan EL: Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv 2008;1:211–217.
2.
Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al: Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, versus sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47–55.
3.
Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, versus placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56–63.
4.
Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S: Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010;121:221–229.
5.
Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC: Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2010;139:591–599.
6.
Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al: A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res 2012;14:343–350.
7.
Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;4: CD006103.
8.
Moore TJ, Furberg CD: Varenicline and suicide. Risk of psychiatric side effects with varenicline. BMJ 2009;339:b4964.
9.
Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S: Suicidal behavior and depression in smoking cessation treatments. PloS One 2011;6:e27016.
10.
Singh S, Loke YK, Spangler JG, Furberg CD: Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359–1366.
11.
European Medicines Agency: European Medicines Agency confirms positive benefit-risk balance for Champix. 2011. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/07/news_detail_001314.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=true; accessed 21 March, 2012.
12.
Prochaska JJ, Hilton JF: Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012;344:e2856.
13.
Gershon AS, Warner L, Cascagnette P, Victor JC, To T: Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 2011;378:991–996.
14.
Andreas S, Batra A, Behr J, Berck H, Chenot JF, Gillissen A, et al: Guidelines for smoking cessation in patients with COPD issued by the Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (in German). Pneumologie 2008;62:255–272.
15.
Van Gaal LF, Mertens IL, De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875–880.
16.
Fagard RH, Nilsson PM: Smoking and diabetes – the double health hazard! Prim Care Diabetes 2009;3:205–209.
17.
Scallan C, Doonan RJ, Daskalopoulou SS: The combined effect of hypertension and smoking on arterial stiffness. Clin Exp Hypertens 2010;32:319–328.
18.
Prochaska JJ: Smoking and mental illness – breaking the link. N Engl J Med 2011;365:196–198.
19.
Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al: Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88–136.
20.
Lancaster T, Stead LF: Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005;2:CD001292.
21.
Hughes JR, Stead LF, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007;1:CD000031.
22.
Stead LF, Perera R, Bullen C, Mant D, Lancaster T: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;1:CD000146.
23.
Twardella D, Brenner H: Effects of practitioner education, practitioner payment and reimbursement of patients’ drug costs on smoking cessation in primary care: a cluster randomised trial. Tob Control 2007;16:15–21.
24.
Gunnell D, Irvine D, Wise L, Davies C, Martin RM: Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805.
25.
Salize HJ, Merkel S, Reinhard I, Twardella D, Mann K, Brenner H: Cost-effective primary care-based strategies to improve smoking cessation: more value for money. Arch Intern Med 2009;169:230–235, discussion 235–236.
26.
Boudrez H, Gratziou C, Messig M, Metcalfe M: Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study. Curr Med Res Opin 2011;27:769–775.
27.
West R, Hajek P, Stead L, Stapleton J: Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005;100:299–303.
28.
Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR: Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64–71.
29.
Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, et al: Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008;63:717–724.
30.
Lee JH, Jones PG, Bybee K, O’Keefe JH: A longer course of varenicline therapy improves smoking cessation rates. Prev Cardiol 2008;11:210–214.
31.
Zeng F, Chen CI, Mastey V, Zou KH, Harnett J, Patel BV: Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims. Clin Ther 2011;33:225–234.
32.
Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J: A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007;23:793–801.
33.
Halperin AC, McAfee TA, Jack LM, Catz SL, McClure JB, Deprey TM, et al: Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat 2009;36:428–434.
34.
Glassman AH, Covey LS, Stetner F, Rivelli S: Smoking cessation and the course of major depression: a follow-up study. Lancet 2001;357:1929–1932.
35.
West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al: Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011;365:1193–1200.
36.
World Health Organization: Global Status Report on Noncommunicable Diseases 2010; http://www.who.int/nmh/publications/ncd_report_full_en.pdf; accessed 21 March, 2012.
37.
Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH: Smoking and mental illness: a population-based prevalence study. JAMA 2000;284:2606–2610.
38.
Patrick DL, Cheadle A, Thompson DC, Diehr P, Koepsell T, Kinne S: The validity of self-reported smoking: a review and meta-analysis. Am J Public Health 1994;84:1086–1093.
39.
Becona E, Miguez MC: Concordance of self-reported abstinence and measurement of expired air carbon monoxide in a self-help smoking cessation treatment. Psychol Rep 2006;99:125–130.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.